Larimar Therapeutics, Inc. 8-K Filing
Ticker: LRMR · Form: 8-K · Filed: Dec 17, 2025 · CIK: 1374690
| Field | Detail |
|---|---|
| Company | Larimar Therapeutics, Inc. (LRMR) |
| Form Type | 8-K |
| Filed Date | Dec 17, 2025 |
| Pages | 4 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
FAQ
What type of filing is this?
This is a 8-K filing submitted by Larimar Therapeutics, Inc. (ticker: LRMR) to the SEC on Dec 17, 2025.
What are the key financial figures in this filing?
Key dollar amounts include: $0.001 (ich registered Common Stock, par value $0.001 per share LRMR Nasdaq Global Market).
How long is this filing?
Larimar Therapeutics, Inc.'s 8-K filing is 4 pages with approximately 1,059 words. Estimated reading time is 4 minutes.
Where can I view the full 8-K filing?
The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.
Filing Stats: 1,059 words · 4 min read · ~4 pages · Grade level 12 · Accepted 2025-12-17 08:00:18
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share LRMR Nasdaq Global Market
Filing Documents
- d42051d8k.htm (8-K) — 30KB
- d42051dex31.htm (EX-3.1) — 75KB
- d42051dex101.htm (EX-10.1) — 100KB
- 0001193125-25-321738.txt ( ) — 367KB
- lrmr-20251216.xsd (EX-101.SCH) — 3KB
- lrmr-20251216_lab.xml (EX-101.LAB) — 18KB
- lrmr-20251216_pre.xml (EX-101.PRE) — 11KB
- d42051d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Below is a list of exhibits included with this Current Report on Form 8-K. Exhibit No. Document 3.1 Certificate of Designation of Preferences, Rights and Limitations of Series A Convertible Preferred Stock* 10.1 Exchange Agreement, dated December 16, 2025, by and between Larimar Therapeutics, Inc. and the Stockholder named therein* 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) * Filed herewith
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Larimar Therapeutics, Inc. By: /s/ Carole S. Ben-Maimon, M.D. Name: Carole S. Ben-Maimon, M.D. Title: President and Chief Executive Officer Date: December 17, 2025